Atriva Therapeutics to present at the BIO-Europe in Hamburg
Tübingen (Germany), October 31, 2019 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, will present at the upcoming 25th Annual International Partnering Conference BIO-Europe®.
The conference is held at the Hamburg Messe in Hamburg, Germany, from November 11th – 13th, 2019. During the conference, CEO Dr. Rainer Lichtenberger and COO Dr. Christian Wallasch will represent the Company and be available for networking and one-on-one meetings. Dr. Lichtenberger will also give a Company Presentation as part of the Infectious Disease Session on November 11, at 17:45. The session will take place in Level 1, Hall B1, Room 7.
About Atriva Therapeutics GmbH
Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different respiratory viral infections. The lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. ATR-002 is under clinical development in a Phase I trial to evaluate safety and tolerability in healthy subjects. The Company owns nine broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2039. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.